Docetaxel and radiation as combined-modality therapy

Area of Science:

• Oncology
• Radiation Oncology
• Medical Oncology

Background:

• Combined-modality treatments improve survival in non-small-cell lung cancer (NSCLC), head and neck, and esophageal cancers.
• Taxanes, including docetaxel, are effective and tolerable in solid tumors and enhance radiation therapy.
• Docetaxel combined with radiation has demonstrated favorable outcomes in phase II trials.

Purpose of the Study:

• To evaluate the efficacy and tolerability of docetaxel in combination with radiation therapy for solid tumors.
• To explore docetaxel and platinum combinations with radiation, particularly in NSCLC.
• To inform future phase III trials for locally advanced NSCLC.

Main Methods:

• Phase II trials investigated docetaxel at 20-30 mg/m2 weekly with concomitant radiation (1.8-2.0 Gy/day, 5 days/week for 5-6 weeks).
• Studies combined docetaxel (20 mg/m2 weekly) with cisplatin (25 mg/m2) or carboplatin (AUC 2) and radiation.
• Ongoing trials examine induction chemotherapy followed by radiation and consolidation chemotherapy.

Main Results:

• Docetaxel and radiation achieved response rates up to 80% in phase II trials.
• Docetaxel-platinum-radiation combinations showed good activity and acceptable toxicity in NSCLC.
• Dose-limiting toxicities included esophagitis or mucositis; specific regimens were well-tolerated.

Conclusions:

• Combined docetaxel and radiation therapy is an active and tolerable approach for NSCLC, head and neck, and esophageal cancers.
• Docetaxel-platinum-radiation combinations represent a promising strategy for NSCLC treatment.
• Further phase III investigations are warranted to confirm efficacy in locally advanced NSCLC.